Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 2, 2004 - Issue 1
Submit an article Journal homepage
64
Views
27
CrossRef citations to date
0
Altmetric
Review

Malaria chemoprophylaxis: when should we use it and what are the options?

Eskild Petersen Department of Infectious Diseases, Aarhus University Hospital Skejby, DK-8200 Aarhus N, Denmark. [email protected]
Pages 119-132 | Published online: 10 Jan 2014

References

  • Macdonald G. The Epidemiology and Control of Malaria. Oxford University Press, Oxford, UK 11 (1957).
  • Kofoed K, Petersen E. The efficacy of chemoprophylaxis against malaria with chloroquine plus proguanil, mefloquine, and atovaquone plus proguanil in travelers from Denmark.j Travel Med. 10,150–154 (2003).
  • Hatton CS, Peto TE, Bunch C, et al Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 411–414 (1986).
  • CDC. Agranulocytosis associated with the use of amodiaquine for malaria prophylaxis. MMWR35,165–166 (1986).
  • CDC. Revised recommendations for preventing malaria in travelers to areas with chloroquine-resistant Plasmodium falciparum. MMWR 34,185-90,195 (1985).
  • Ognibene AJ. Agranulocytosis due to dapsone. Ann. Intern. Med. 72,521–524 (1970).
  • Friman G, Nystrom-Rosander C, Jonsell G, Bjorkman A, Lekas G, Svendstrup B. Agranulocytosis associated with malaria prophylaxis with Maloprim. Br. Med. J Cilia. Res. 286,1244–1245 (1983).
  • •First report of hematological side effects from maloprim.
  • Andersen SL, Oloo AJ, Gordon DM, et al Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Cilia. Infect. Dis 26, 146–150 (1998).
  • Taylor WR, Richie TL, Fryauff DJ, et al Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Cilia. Infect. Dis. 28, 74–81 (1999).
  • Heigh B. Clinical and parasitological studies on immunity to Plasmodium falciparum malaria in children. Scand. J Infect. Dis 102 (Suppl.), 1–53 (1996).
  • Garnham PCC. Malaria parasites of man: life-cycles and morphology (excluding ultrastructure). In: Malaria. Principles and Practices of Malariology Wernsdorfer WH, McGregor I (Eds). Churchill Livingstone, Edinburgh, UK 61–96 (1988).
  • Hill DR, Behrens RH, Bradley DJ. The risk of malaria in travelers to Thailand. Trans. R. Soc. Trop. Med. Hyg. 90,680–681 (1996).
  • Phillips-Howard PA, Radalowicz A, Mitchell J, Bradley DJ. Risk of malaria in British residents returning from malarious areas. bk Med. J300, 499–503 (1990).
  • Molle I, Petersen E, Buhl MR. Retrospective evaluation of exposure to Pfa/ciparunz using antibodies to circumsporozoite protein and to cultured R falciparum antigens. Scand. Infect. Di& 31,69–71 (1999).
  • Bloland P Drug resistance in malaria. WHO. Geneva, Switzerland (2001).
  • Bruce-Chwatt LJ, Black RH, Canfield CJ, Clyde DF, Peters W Wernsdorfer WH. Chemotherapy of Malaria. WHO Monograph Series No. 2Z Revised Second Edition. Geneva, Switzerland 105 (1986).
  • Moore DV, Lanier JE. Observations on two Plasmodium falciparum infections an abnormal response to chloroquine. Am. J Trop. Med. Hyg. 10,5–9 (1961).
  • •First report of chloroquine resistance
  • Harinasuta T, Migasen S, Boonag D. Chloroquine resistance in Plasmodium falciparum in Thailand. UNESCO 1st regional symposium on scientific knowledge of tropical parasites. 5–9 Nov. 1962. University of Singapore, Singapore. 148–153.
  • •First report of chloroquine resistance in Thailand.
  • Centres for disease Control. Chloroquine-resistant malaria acquired in Kenya and Tanzania. Denmark, Georgia and New York. MMWR27, 463–464 (1978).
  • •First report of chloroquine resistance in Africa.
  • Adou-Bryn KD, Krelo K, Akoussi CFG, et al Efficacité thérapeutique de la chloroquine dans le traitement du paludisme simple dfi. a Plasmodium falciparum des consultants hospitaliers dans la centre de la Cote d'Ivoire (1997-2000). Bull. Soc. PathoL Exot. 95, 262–264 (2002).
  • Kublin JG, Cortese JF, Njunju EM, et al Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J. Infect. Dis. 187,1870–1875 (2003).
  • •First firm documentation of reversal of drug resistance against chloroquine after cessation of use.
  • Taylor WR, Widjaja H, Richie TL, et al C hloro qu ine/d oxycycl in e combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, indonesia. Am. J Trop. Med. Hyg. 64, 223–228 (2001).
  • •Document on extensive chloroquine resistance in Plasmodium vivax.
  • Adams ARD, Seaton DR. Resistance to paludrine developed by a strain of Plasmodium falciparurn. Trans. R. Soc. Trop. Med. Hyg. 42,314–315 (1949).
  • Field JW, Edeson JFB. Paludrine-resistant falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 43,233–236 (1949).
  • •First report of resistance to dihydrofolate reductase inhibitors after field use.
  • Avery-Jones S. Resistance of I? falciparum and P.' rnalariae to pyrimethamine (Daraprim) following mass treatment with this drug. A preliminary note. East Air. Med. J.31, 47–49 (1954).
  • McGregor IA, Smith DA. Daraprim in treatment of malaria: a study of its effects in falciparum and quartan infections in West Africa. Br. Med. 730–734 (1952).
  • Wilson T. Symposium on Daraprim (Discussion). Trans. R. Soc. Trop. Med. Hyg. 46,499–500 (1952).
  • Dodge JS. Malaria chemoprophylaxis in four schools in Kaduna, Northern Nigeria. West Afr. Med. J. 16,55–58 (1967).
  • Ogutu RB, Smoak BL, Nduati RW, Mbori-Ngacha DA, Mwathe F, Shanks GD. The efficacy of pyrimethamine-sulfadoxine resistance of Plasmodium falciparum malaria in Kenyan children. Trans. R. Soc. Trop. Med. Hyg. 94,83–84 (2000).
  • Trigg JK, Mbwana H, Chambo O, Hills E, Watkins W, Curtis CF. Resistance to pyrimethamine-sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil-dapsone. Acta Tropica 63, 185–189 (1997).
  • MacArthur J, Stennies GM, Macheso A, et al. Efficacy of mefloquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum infection in Machinga District, Malawi, 1998. Am. J Trop. Med. Hyg. 65,679–684 (2001).
  • Bwijo B, Kaneko A, Takechi M, etal. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Trop. 85, 363–373 (2003).
  • Coatney GR. Pitfalls in a discovery: the chronicle of chloroquine. Am. J. Trop. Med. Hyg. 12,121–128 (1963).
  • Phillips-Howard P, Kuile FO. CNS adverse events associated with antimalarial agents. Drug Safety12,370-383 (1995).
  • Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet ii: 278 (1959).
  • WHO. Advances in malaria chemotherapy. Report of a WHO scientific group. (WHO Technical report series No. 711). Geneva, Switzerland (1984).
  • WHO. Practical Chemotherapy of Malaria. Report of a WHP Scientific Group. (WHO Technical Report Series No. 805). Geneva, Switzerland (1990).
  • Arthur JD, Echeverria P, Shanks GD, Karwacki J, Bodhidatta L, Brown JE. A comparative study of gastrointestinal infections in US soldiers receiving doxycycline or mefloquine for malaria prophylaxis. Am. J. Trop. Med. Hyg. 43, 608–613 (1990).
  • Shanks GD, Roessler P, Edstein MD, Rieckmann KH. Doxycycline for malaria prophylaxis in Australian soldiers deployed to United Nations missions in Somalia and Cambodia Mil. Med. 160,443–445 (1995).
  • Baudon D, Martet G, Pascal B, Bernard J, Keundjian A, Laroche R. Efficacy of daily antimalarial chemoprophylaxis in tropical Africa using either doxycycline or chloroquine-proguanil; a study conducted in 1996 in the French Army. Trans. R. Soc. Trop. Med. Hyg. 93,302–303 (1999)
  • Sanchez JL, DeFraites RF, Sharp TW, Hanson RK. Mefloquine or doxycycline for US troops in Somalia. Lancet 341, 1021–1022 (1993).
  • Ohrt C, Richie TL, Widjaja H, etal. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. Ann. Intern. Med. 126,963–972 (1997).
  • Weiss WR, Oloo AJ, Johnson A, Koech D, Hoffman SL. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline and chloroquine plus proguanil. Infect. Dis. 171,1569–1575 (1995).
  • Rieckmann KH, Yeo AE, Davis DR, etal. Recent military experience with malaria chemoprophylaxis. Aust. Med. J 158, 446–449 (1993).
  • Pages F, Boutin J-P, Meynard J-B, etal. Tolerability of doxycycline monohydrate salt vs. chloroquine-proguanil in malaria chemoprophylaxis. Trop. Med. Intl. Hlth.7, 919–24 (2002).
  • Rieckmann KH, Trenholme GM, Williams RL, Carson PE, Frischer H, Desjardins RE. Prophylactic activity of mefloquine hydrochloride (WR 142490) in drug-resistant malaria. Bull. WHO51,375-377 (1974).
  • •Phase I and II trials of mefloquine.
  • Pearlman El Doberstyn EB, Sudsok S, Thiemanun W, Kennedy RS, Canfield CJ. Chemosuppressive field trials in Thailand. IV. The suppression of Plasmodium falciparum and Plasmodium vivax parasitemias by mefloquine (WR 142,490, A 4-quinolinemethanoll. Am. J. Trop. Med. Hyg. 29,1131–1137 (1980).
  • •First phase III trial of mefloquine.
  • Hellgren U, Angel VH, Bergqvist Y, Arvidsson A, Forero-Gomez JS, Rombo L. Plasma concentrations of sulfadoxine-pyrimethamine and of mefloquine during regular long-term malaria prophylaxis. R Soc. Trop. Med. Hyg. 84,46–49 (1990).
  • •Study demonstrating that long-term use of mefloquine did not result in accumulation of the drug.
  • Patchen LC, Campbell CC, Williams SB. Neurologic reactions after a therapeutic dose of mefloquine. N Engl. J. Med. 321, 1415–1416 (1989).
  • Havaldar PV, Mogale KD, Mefloquine induced psychosis. Ped. Infect. Dis. J. 19, 166–167 (2000).
  • WHO. Review of central nervous system adverse events related to the antimalarial drug mefloquine (1985-1990). Unpublished document WHO/MAL/91.1063. WHO, Geneva, Switzerland (1991).
  • Weinke T, Trautmann M, Held T, etal. Neuropsychiatric side effects after the use of mefloquine. Am.j Trop. Med. Hyg. 45, 86–91 (1991).
  • Phillips-Howard PA, ter Kuile FO. CNS adverse events associated with antimalarial agents. Fact or fiction? Drug Safety12,370-383 (1995).
  • Bern JL, etal. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J. Trop. Med. Hyg. 95,167–179 (1992).
  • Croft AMJ, Garner P Mefloquine for preventing malaria in non-immune adult travelers. Cochrane Library Issue 3: update software (2000).
  • Barrett, PJ, Emmins PD, Clarke PD, Bradley, DJ. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travelers. Br. Med. J. 313,525–528 (1996).
  • Phillips MA, Kass RB. User acceptability patterns for mefloquine and doxyclycline malaria chemoprophylaxis. J. Travel Med. 3,40–45 (1996).
  • •Study showing that mefloquine tolerability is gender dependent.
  • Riemsdijk MM van Sturkenboom MC, Schilthuis HJ, Stricker BH. Spontaneous reports of psychiatric adverse effects to mefloquine in the Netherlands. Br. J Clin. Pharmacol. 44,105–106 (1997).
  • Ehrman FC, Ellis JM, Young MD. Plasmodium vivax Chesson strain. Science 101,377 (1945).
  • •First report of innate resistance to primaquine.
  • Schwartz E, Regev-Yochay G. Primaquine as prophylaxis for malaria for non-immune travelers: a comparison with mefloquine and doxycycline. Clin. Infect. Dis. 29,1502–1506 (1999).
  • Nasveld P, Kitchener S, Edstein M, Rieckmann. Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel. Trans. R. Soc. Trop. Med. Hyg. 96,683–684 (2002).
  • Shanks GD, Oloo AJ, Aleman GM, etal. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin. Infect. Dis. 33,1968–1974 (2001).
  • Hale BR, Owusu-Agyei S, Fryauff DJ, et al. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin. Infect. Dis. 36(5), 541–549 (2003).
  • Petersen E, Heigh B, Hanson AP, Björkman A, Flachs H. In vitro and in vivo susceptibility of P/asmodium fa/ciparum isolates from Liberia to pyrimethamine, cycloguanil and chlorcycloguanil. Ann. Trop. Med. Parasitol. 84,563–571 (1990).
  • •First report of higher activity of chlorcycloguanil compared to cycloguanil.
  • Petersen E, Flachs H, Heigh B, Hanson AP, Hvidberg EE Human pharmacokinetics of chlorproguanil and its two main metabolites at different dose levels. J Trop. Med. Hyg. 94,199–205 (1991).
  • Lucas AO, Hendrickse RG, Okubadejo OA, Ricards WH, Neal RA, Kofie BA. The suppression of malaria parasitemia by pyrimethamine in combination with dapsone or sulfamethoxine. Trans. R. Soc. Trop. Med. Hyg. 63,216–229 (1969).
  • Black RH. Malaria in the Australian army in South Vietnam: successful use of a proguanil-dapsone combination for chemoprophylaxis of chloroquine-resistant falciparum malaria. Med. J Aust. 1, 1265–1270 (1973).
  • Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC. Long-term malaria prophylaxis with weekly mefloquine. Lancet 341,848–851 (1993).
  • Steffen R, Fuchs E, Schildknecht J, et al Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet341,1299-1303 (1993).
  • Behrens RH, Bradley DJ, Snow RVV, Marsh K. Impact of UK malaria prophylaxis polic y on imported malaria. Lancet348,344-345 (1996)
  • Peragallo MS, Sabatinelli G, Majori G, Cali G, Sarnicola G. Prevention and morbidity of malaria in non-immune subjects: a case control study among Italian troops in Somalia and Mozambique, 1992-94. Trans. R. Soc. Trop. Med. Hyg. 91,343–346 (1997).
  • Marsh K. Malaria disaster in Africa. Lancet 352,924 (1998).
  • Trape JE Impact of chloroquine resistance on malaria mortality. C. R. Acad. Sci. Paris 321,689–697 (1998).
  • WHO international Travel and Health 1999. WHO, Geneva (1999).
  • Sarrouy J, Cellier C, Migliani R, et al Chemophrophylaxis of Plasmodium falciparum malaria by a combination of 100 mg chloroquine and 200 mg proguanil per day in a zone III of chloroquine resistance (Gabon). Study of 437 French soldiers. Bull. Soc. Pathol. Exot. 84,80–93 (1991).
  • Petersen E, Ronne T, Ronn A, Bygbjerg IC, Larsen SO. Reported side effects to chloroquine, chloroquine plus proguanil and mefloquine as chemophrophylaxis against malaria in Danish travelers. J Tray. Med. 7, 79–84 (2000).
  • Hudson AT, Dickins M, Ginger CD, etal. 566C80: a broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp. Clin. Res. 17, 427–435 (1991).
  • Srivastava IK, Rottenberg H, Vaidya AB. Atovaquone, a broad spectrum antiparasitic drug, collapse mitochondrial membrane potential in a malaria parasite. J. Biol. Chem. 272,3961–3966 (1997).
  • Davies CS, Pudney M, Nicolas JC, Sinden RE. The novel hydroxynaphthoquinone 566C80 inhibits the development of liver stages of Plasmodium berghei cultured in vitro. Parasitology106,1-6 (1993).
  • •First report of complete inhibition of lever schizonts by atovaquone.
  • Shapiro TA, Ranasinha CD, Kumar N, Barditch-Crovo P. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am. j Trop. Med. Hyg. 60, 831–836 (1999).
  • Berman JD, Nielsen R, Chulay JD. Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. Trans. R. Soc. Trop. Med. Hyg. 95, 429–432 (2001).
  • •Review of early human trials of volunteers infected by Plasmodium infected mosquitoes.
  • Shanks GD, Gordon DM, Klotz FW, et al Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin. Infect. Dis. 27, 494–499 (1998).
  • Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG. Randomised-placebo controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet351, 709–713 (1998).
  • Sukwa TY, Mulenga M, Chisdaka N, Roskell NS, Scott TR. A randomised, double-blind, placebo controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am. J Trop. Med. Hyg. 60,521–525 (1999).
  • Shanks GD, etal. Atovaquone and Proguanil Hydrochloride for prophylaxis of malaria.j Travel Med. 6 (Supp1.1), 21–27 (1999).
  • Heigh B, Clarke PD, Camus D, etal, and the Malarone International Study Team. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travelers: a randomised, double-blind study. Lancet356,1888-1894 (2000).
  • •First randomized trial of atovaquone/proguanil in nonimmune travelers.
  • Overbosch D, Schilthuis H, Bientzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in non-immune travelers: results from a randomized, double-blind study. Clin. Infect. Dis. 33,1015–1021 (2001).
  • Looareesuwan S, Viravan C, Webster HK, Kyle DE, Canfield CJ. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs for treatment of acute uncomplicated malaria in Thailand. Arn. I Trop. Med. Hyg. 54,62–66 (1996).
  • Shanks GD, Ragama BO, Oloo AJ. Time to reappearance of malaria parasites following various drug treatment regimens in a holoendemic area of western Kenya 1999. Trans. R. Soc. Trop. Med. Hyg. 93, 304–305 (1999).
  • Radloff PD, Philipps J, Hutchinson D, Kremsner PG. Atovaquone plus proguanil is an effective treatment for F.' ovale and F.' rnalariae malaria. Trans. R. Soc. Trop. Med. Hyg. 90, 682 (1996).
  • Petersen E. The safety of atovaquone/proguanil in long-term malaria prophylaxis of non-immune adults.Travel Med. 10 (Suppl 1), S13—S15 (2003).
  • McKeage K, Scott U. Atovaquone/proguanil. A review of its use for the prophylaxis of Plasmodium fakiparurn malaria. Drugs 63, 597–623 (2003).
  • Hornstein OP, Ruprecht KW Fansidar-induced Stevens-Johnson Syndrome. N Engl. Med. 307, 1529–1530 (1982)
  • Friman G, Nystrom-Rosander C, Jonsell G, Bjorkman A, Lekas G, Svendstrup B. Agranulocytosis associated with malaria prophylaxis with Maloprim. Br. Med. J Clin. Res. 286, 1244 —1245 (1983).
  • •First report of hematological side effects from maloprim.
  • Alonso PL, Lindsay SW, Armstrong Schellenberg JR, etal. A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, West Africa. 6. The impact of the interventions on mortality and morbidity from malaria. Trans. R. Soc. Trop. Med. Hyg. Suppl 2, 37–44 (1993).
  • •First trial comparing efficacy of impregnated bednets and chemoprophylaxis.
  • David KP, Marbiah NT, Lovgren P, Greenwood BM, Petersen E. Hyperpigmented dermal macules in children following the administration of Maloprim for malaria chemoprophylaxis. Trans. R. Soc. Trop. Med. Hyg. 91, 204–208 (1997).
  • •First report of adverse events in long-term users of dapsone/pyrimethamine
  • Watkins WM, Brandling-Bennet AD, Nevin CG, etal. Chlorproguanil/dapsone for the treatment of non-severe Plasmodium falciparum malaria in Kenya: a pilot study. Trans. R. Soc. trop. Med. Hyg. 82, 398–403 (1988).
  • •First field trial of chlorproguanil/dapsone, now launched as LapDap®.
  • Winstanley P, Watkins W, Muhia D, Szwandt S, Amukoye E, Marsh K. Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children. Pharmokinetics and therapeutic range. Trans. R. Soc. Trop. Med. Hyg. 91, 322–327 (1997).
  • Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley E, Hills E, Watkins W Chlorproguanil-dapsone for treatment of drug resistant falciparum malaria in Tanzania. Lancet358, 1218–1223 (2001).
  • WHO. The use of antimalarial drugs. Report of a WHO informal consultation. 13— 17 November 2001. WHO/CDS/RBM/2001.33
  • Wolfe MS, Cordero JE Safety of chloroquine in chemosuppression of malaria during pregnancy. Br. Med. J 290, 1466–1467 (1985).
  • Klinger G, Morad Y, Westall CA, etal. Ocular toxocity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 358, 813–814 (2001).
  • Vanhauwere B, B, Maradit H, Kerr L. Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy. Am. J Trop. Med. Hyg. 58, 17–21 (1998).
  • •Largest study of teratogenic effect of mefloquine.
  • Smoak BL, Writer JV, Keep LW, Cowan J, Chantelois JL. The effects of inadvertent exposure to mefloquine chemoprophylaxis on pregnancy outcomes and infants of US army servicewomen. J Infect. Dis. 176, 831–833 (1997).
  • Nosten F, Vincenti M, Simpson J, Yei P, Thwai KL, Vries A de, Chongsuphajaisiddhi T, White NJ. The effects of mefloquine treatment in pregnancy. Clin. Infect. Dis. 28, 808–815 (1999).
  • WHO International Travel and Health. Geneva, Switzerland (2003).
  • Editorial. Pyrimethamine combinations in pregnancy. Lancetii, 1005–1007 (1983).
  • Anon. Sudden death in a traveler following halofantrine administration — Togo, 2000. Can. C01771771117. Dis. Rep. 27, 120–121, 124 (2001).
  • Touze JE, Heno P, Fourcade L, etal. The effects of antimalarial drugs on ventricular repolarization. Am. J Trop. Med. Hyg. 67, 54–60 (2002).
  • Marbiah NT, Petersen E, David K, Magbity E, Lines J, Bradley DJ. A controlled trial of lambda-cyhalothrin-impregnated bed nets and/or dapsone/pyrimethamine for malaria control in Sierra Leone. Am J Trop Med Hyg. 58, 1–6 (1998).
  • Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, Pasvol G. Malarone treatment failure and in vivo confirmation of resistance of Plasmodium falciparum isolate from lagos, Nigeria. Malaria J. 1, 1–4 (2002).
  • •First report of resistance to atovaquone/proguanil after treatment.
  • Schwartz E, Bujanover S, Kain KC. Genetic confirmation of atovaquone-proguanil resistant Piasznodium faitiparum malaria acquirted by a non-immune traveler to East Africa. Cilia. Infect. Dis. 37, 450–451 (2003).
  • Peters W, Stewart LB, Robinson BL. The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines. Ann. Trop. Med. Parasitol. 97, 221–236 (2003).
  • •Study of the development of resistance in P yoelli in a rodent model of chloroquine, mefloquine alone and in combination with primaquine and tafenoquine.

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.